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Success in the introduction of novel, effective and safe
analgesics has been notably limited over the past ten years
even though existing treatments have low responder rates
and a high side effect burden. The pipeline of compounds
acting on novel targets is very restricted and there have
been many disappointments with drugs that appeared
promising in preclinical studies, failing repeatedly in clini-
cal trials. We have to recognize that something is funda-
mentally wrong with the industry standard approach to
the selection of targets, identification of hits, validation of
leads and proof of concept clinical studies. A radically
alternative strategy is required, one that is driven by the
patient and focused on disease phenotype. I will discuss
what such an approach may look like and how it may
contribute to new therapeutics.
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